In this heavily pretreated cohort, midostaurin showed limited activity in FLT3-mutated AML, whereas in r/r KMT2A-rearranged ALL, which is often associated with high-level expression of mutation-negative FLT3 (36), no clinical activity of midostaurin was demonstrated (37). The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.